U.S. markets close in 4 hours 49 minutes

  • S&P 500

    4,379.58
    +10.03 (+0.23%)
     

  • Dow 30

    34,962.30
    +92.14 (+0.26%)
     

  • Nasdaq

    14,719.42
    +17.50 (+0.12%)
     

  • Russell 2000

    2,267.84
    -12.16 (-0.53%)
     

  • Crude Oil

    73.86
    -0.70 (-0.94%)
     

  • Gold

    1,805.40
    -5.20 (-0.29%)
     

  • Silver

    26.31
    +0.07 (+0.27%)
     

  • EUR/USD

    1.1868
    -0.0013 (-0.11%)
     

  • 10-Yr Bond

    1.3610
    +0.0050 (+0.37%)
     

  • GBP/USD

    1.3892
    -0.0010 (-0.07%)
     

  • USD/JPY

    110.3040
    +0.2750 (+0.25%)
     

  • BTC-USD

    33,472.14
    -498.90 (-1.47%)
     

  • CMC Crypto 200

    821.10
    -24.54 (-2.90%)
     

  • FTSE 100

    7,122.60
    +0.72 (+0.01%)
     

  • Nikkei 225

    28,569.02
    +628.60 (+2.25%)
     

Global Ulcerative Colitis Clinical Markets Report 2021-2027: Treatments, Epidemiology, Marketed & pipeline Drugs, Regulatory Events, Future Trends, Unmet Needs

·5 min read

DUBLIN, July 12, 2021 /PRNewswire/ -- The "Disease Analysis: Ulcerative Colitis" report has been added to ResearchAndMarkets.com's offering.

Research and Markets Logo
Research and Markets Logo

UC typically presents with bloody diarrhea, which may manifest alongside mucus, rectal urgency, tenesmus, and abdominal pain. The disease course is relapsing and remitting with intermittent periods of acute exacerbation, which may be serious enough to warrant therapy escalation, hospitalization, or even colectomy.

Latest Key Takeaways

  • As specialty products, therapies for ulcerative colitis (UC) can be expensive, and formulary positioning is paramount to product uptake. Payers are settled in vital contracts that lead them to prioritize broad immunology drugs Humira and Remicade. This has posed a high barrier to newer entrants to the market, which cannot compete in volume and rebates. Biosimilar and generic competition will further undermine the likely premium pricing of newer and pipeline products.

  • Pivotal upcoming events in the forecast period include the entries of biosimilar adalimumab and generic tofacitinib. Biosimilar adalimumab will enter the US market from 2023, while generic tofacitinib is expected to enter the US market at the end of 2025. Notably, generics have fewer barriers to entry than biosimilars due to numerous factors, including their less complex nature and long-standing familiarity, which facilitates much faster and stronger erosion of branded sales.

  • Nevertheless, the UC market is projected to expand, propelled by a growing patient caseload and the introduction of pipeline products. The publisher estimates that in 2018, there were 12.6 million prevalent cases of UC worldwide, and forecasts that number to increase to 13.5 million prevalent cases by 2027.

  • The UC pipeline holds multiple novel prospects in terms of distinct mechanisms of action and biologics with more convenient formulations. The market will welcome sphingosine 1-phosphate (S1P) receptor modulators etrasimod and Zeposia, interleukin-23 (IL-23) modulator mirikizumab, and toll-like receptor (TLR) 9 modulator Kappaproct. There has been a positive response to Xeljanz as the first novel oral drug competing with biologics for UC, and other companies have recognized this opportunity to provide ease of administration with oral etrasimod, Zeposia, and Rinvoq. Once these products reach the market, they will provide more options for UC patients beyond the established, non-oral anti-TNF class, which is currently the mainstay of treatment. It is likely that these novel products will initially compete at later lines of therapy after the anti-TNF inhibitors, given the latter's enduring stronghold at the first line of biologic therapy.

  • Although the anti-TNF class are the cornerstone of treatment, ~10-30% of patients are non-responders to initial treatment and ~23-46% of patients lose response over time. Additionally, the class has black box warnings for the risk of serious infections and malignancy. These drugs are favored due to long-standing physician familiarity and prioritization in formularies; however, they do not satisfy persisting unmet needs in the UC market.

  • Critical unmet needs and opportunities include demonstrating strong efficacy to treat inadequate responders, clinically balanced drugs that offer both efficacy and safety, producing superior data over anti-TNF inhibitors and available drugs in the same class through head-to-head trials, and competitive pricing, which is essential to facilitate better positioning in the treatment algorithm.

Key Topics Covered:

OVERVIEW

  • Latest key takeaways

DISEASE BACKGROUND

  • Definition

  • Patient segmentation

TREATMENT

  • ACG treatment guidelines

  • ECCO treatment guidelines

  • NICE treatment guidelines

EPIDEMIOLOGY

  • Prevalence methodology

MARKETED DRUGS

PIPELINE DRUGS

KEY REGULATORY EVENTS

  • Alberta Expands Biosimilar Switching With Adalimumab

  • Sandoz Confirms Launch Of Humira Rival In Canada

  • Celltrion Wins Global First Approval For High-Concentration Humira Biosimilar

  • Celltrion Wins Race For High-Concentration Adalimumab

  • Tentative Xeljanz XR Approval Among Several For Zydus Cadila

  • Extra Indications Approved For Celltrion's Remsima SC

  • FDA Approves Mylan's Humira Biosimilar

  • Zeria UC Drug Finally To Market

  • EU Approves Takeda's Injectable Entyvio for IBD

PROBABILITY OF SUCCESS

LICENSING AND ASSET ACQUISITION DEALS

  • LG Chem, TransThera Agree To Immune Disease Partnership

  • Merck & Co. Buys Pandion, Building Out Capability In Autoimmune Disease

  • Scipher Hopes IBD Alliance With Galapagos Is The First Of Many

CLINICAL TRIAL LANDSCAPE

  • Sponsors by status

  • Sponsors by phase

  • Recent events

DRUG ASSESSMENT MODEL

  • Biologic DMARDs

  • Non-biologic DMARDs

  • DNA-based immunomodulatory sequence

MARKET DYNAMICS

FUTURE TRENDS

  • Novel pipeline products are poised to diversify the UC market

  • Brands will face headwinds as the UC market is penetrated by biosimilars and generics

CONSENSUS FORECASTS

RECENT EVENTS AND ANALYST OPINION

  • ABX464 for Ulcerative Colitis (May 24, 2021)

  • Jyseleca for Ulcerative Colitis (March 4, 2021)

  • Rinvoq for Ulcerative Colitis (February 22, 2021)

  • SHR0302 for Ulcerative Colitis (February 4, 2021)

  • AJM300 for Ulcerative Colitis (January 13, 2021)

  • Omilancor for Ulcerative Colitis (January 4, 2021)

  • Jyseleca for Ulcerative Colitis (December 15, 2020)

  • Rinvoq for Ulcerative Colitis (December 9, 2020)

  • Jyseleca for Ulcerative Colitis (October 12, 2020)

  • Etrolizumab for Ulcerative Colitis (October 11, 2020)

  • Zeposia for Ulcerative Colitis (October 10, 2020)

  • Etrolizumab for Ulcerative Colitis (August 9, 2020)

  • Etrolizumab for Ulcerative Colitis (August 9, 2020)

  • Zeposia for Ulcerative Colitis (June 2, 2020)

  • Jyseleca for Ulcerative Colitis (May 20, 2020)

  • Neihulizumab for Ulcerative Colitis (May 4, 2020)

KEY UPCOMING EVENTS

KEY OPINION LEADER INSIGHTS

UNMET NEEDS

  • Treatments that improve the natural history of UC

  • Effective, well-tolerated treatments that induce rapid and sustained remission

  • There is critical unmet need for predictive biomarkers

  • Novel oral treatments

BIBLIOGRAPHY

APPENDIX

For more information about this report visit https://www.researchandmarkets.com/r/oh265g

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1904
Fax (outside U.S.): +353-1-481-1716

Cision
Cision

View original content:https://www.prnewswire.com/news-releases/global-ulcerative-colitis-clinical-markets-report-2021-2027-treatments-epidemiology-marketed--pipeline-drugs-regulatory-events-future-trends-unmet-needs-301331579.html

SOURCE Research and Markets

Recommended Stories

  • Celldex's stock jumps on positive data from early-stage, open-label clinical trial for hives treatments

    Shares of Celldex Therapeutics Inc. soared 43.1% in premarket trading on Monday after the company shared positive data from an ongoing, open-label Phase 1b clinical trial for an experimental treatment for hives. Celldex said that 95% of participants diagnosed with two forms of chronic inducible urticaria reported a complete response to treatment and 5% had a partial response. The data was presented Friday during the European Academy of Allergy and Clinical Immunology Annual Congress. The study h

  • Does This Shocking CDC Statement Mean Trouble for Pfizer and Moderna?

    Coronavirus vaccine leaders Pfizer (NYSE: PFE) and Moderna (NASDAQ: MRNA) announced earlier this year that they'd launched clinical trials of booster shot candidates -- and you could almost hear the world's collective sigh of relief. As coronavirus variants gained ground, everyone's big worry was staying ahead of them. Moderna has said it aims to bring a booster to market this fall.

  • Pfizer Will Make the Case for Booster Dose to Federal Regulators

    The meeting comes days after the company said it would seek approval for a booster dose, drawing an unusual rebuke from federal regulators.

  • BioCryst Shares 96-Week Orladeyo Data Highlighting 80% Reduction In HAE Attacks

    BioCryst Pharmaceuticals Inc (NASDAQ: BCRX) has announced 96-week data from the Phase 3 APeX-2 trial for Orladeyo (berotralstat), showing a sustained reduction in hereditary angioedema (HAE) attacks patients. The HAE patients who were randomized to receive 150 mg of oral, once-daily Orladeyo at the start of the trial had an 80% average reduction in their mean attack rate per month during weeks 25-96 of the trial, compared to baseline. Median attack rates also decreased from 2.7 attacks/month at

  • Tetra Bio-Pharma Accelerates REBORN1© Trial

    Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-derived drug discovery and development announced today that the Central Ethics Committee has approved the proposed protocol modifications allowing additional immediate release oral opioids to be used as comparators in the REBORN1© study. Expanding to three (3) immediate release oral opioids will allow for the acceleration of patient enrolment in the REBORN1© trial.

  • Novo Nordisk to buy Prothena's heart drug in deal worth up to $1.2 billion

    The acquisition is in line with Novo's strategy to diversify its core insulin portfolio that has been facing tough competition, prompting it to turn toward newer diabetes and obesity drugs to revive growth. Under the agreement, Prothena will receive $100 million in upfront and near-term clinical milestone payments for PRX004, currently in a mid-stage trial. Prothena in December had reported positive data from an early-stage trial of PRX004 to treat hereditary ATTR amyloidosis, a life-threatening genetic disease that affects the heart, nerves and other organs.

  • 3M Oral Care Introduces Next-Generation Clear Aligner System

    3M Oral Care has introduced Clarity Aligners Flex + Force: a new aligner system that empowers orthodontists to choose from two unique aligner materials in one treatment design and gives patients a customized treatment experience.

  • Fauci Says ‘It's Horrifying’ to See CPAC Crowd Cheering Low Vaccination Rates

    CNNThe nation’s top infectious disease expert expressed horror on Sunday over attendees of a conservative political conference loudly applauding the inability of the federal government to hit its vaccine goals.With new variants of COVID-19 now surging in areas with low vaccination rates and right-wing media promoting vaccine hesitancy to its viewers, the Conservative Political Action Conference in Texas invited noted “Covid Contrarian” Alex Berenson to fearmonger about the safe and effective cor

  • Never Eat or Drink This During a Heat Wave, Experts Say

    With temperatures climbing to record-breaking levels across the country, everyone should be doing what they can to stay safe. Drinking water and wearing sunscreen (preferably with an SPF of 30 or above) can help protect you during a heat wave, but there are also certain foods and beverages you should avoid while trying to beat the heat—and they're not what you might think. Read on to find out what four things experts say you should never consume as temperatures climb.RELATED: Never Put This on Y

  • Dr. Anthony Fauci breaks down booster debate as concerns over Delta variant rises

    Over the past week, new coronavirus cases are up by 66%. With less than half of the country fully vaccinated, the highly infectious Delta variant now makes up more than 50% of U.S. cases. President Biden's chief medical adviser Dr. Anthony Fauci joins “CBS This Morning” to discuss vaccine boosters and Delta variant concerns.

  • Dr. Fauci Warns These States Will Have Next Surge

    COVID-19 cases are rising in 29 states. That's why this pandemic is nowhere near over, although it once appeared that way. In response, Dr. Anthony Fauci, the chief medical advisor to the President and the director of the National Institute of Allergy and Infectious Diseases, appeared on The Situation Room With Wolf Blitzer to issue a warning, about certain areas of America that are in more danger than others—and it's a message we all need to hear. Read on for five life-saving pieces of advice,

  • This Trick Can Strengthen Your Heart in Minutes, Says New Study

    Heart health is complicated, and the best approach is to pursue multiple strategies, including diet and exercise. But a new study found that one simple trick—five minutes of breathing exercises, performed six days a week—can lower blood pressure and protect your heart. Read on—to ensure your health and the health of others, don't miss these Sure Signs You Have "Long" COVID and May Not Even Know It.Results were on par with blood pressure medication—and better than exerciseAccording to the study,

  • Covid vaccine: Thailand decides to mix jabs as cases spike

    The decision comes after hundreds of medical workers caught Covid despite being fully vaccinated.

  • Whoopi Goldberg Gives Fans a Health Update Following Recent Absence From ‘The View’

    She was “laying in a hospital room” and is now using a walker.

  • Covid Australia: 'Graphic' vaccine advert sparks backlash

    Critics say the clip of a woman gasping for air is unfair to young people who can't get a vaccine yet.

  • Biden administration reportedly 'running out of ideas' for boosting pace of vaccinations

    Biden administration reportedly 'running out of ideas' for boosting pace of vaccinations

  • A COVID Test as Easy as Breathing

    In May, musicians from dozens of countries descended on Rotterdam, the Netherlands, for the Eurovision Song Contest. Over the course of the competition, the performers — clad in sequined dresses, ornate crowns or, in one case, an enormous pair of angel wings — belted and battled it out for their chance at the title. But before they were even allowed onstage, they had to pass another test: a breath test. When they arrived at the venue, the musicians were asked to exhale into a water-bottle-sized

  • Merck, Ridgeback Highlight Interim Molnupiravir Data In Non-Hospitalized COVID-19 Patients

    Merck & Co Inc (NYSE: MRK) and its collaborating partner Ridgeback Biotherapeutics announced the presentation of previously announced Phase 2 interim results from two Phase 2/3 clinical trials of molnupiravir in non-hospitalized COVID-19 patients. The data were presented at the European Congress of Clinical Microbiology & Infectious Diseases. In addition, Merck plans to initiate a clinical program to evaluate molnupiravir for post-exposure prophylaxis in 2H of 2021. As reported earlier, the perc

  • Pfizer to discuss COVID-19 vaccine booster with US officials

    Pfizer says it plans to meet with top U.S. health officials Monday to discuss the drugmaker’s request for federal authorization of a third dose of its COVID-19 vaccine as President Joe Biden’s chief medical adviser acknowledged that "it is entirely conceivable, maybe likely” that booster shots will be needed. The company said it was scheduled to have the meeting with the Food and Drug Administration and other officials Monday, days after Pfizer asserted that booster shots would be needed within 12 months. Pfizer’s Dr. Mikael Dolsten told The Associated Press last week that early data from the company’s booster study suggests people’s antibody levels jump five- to 10-fold after a third dose, compared to their second dose months earlier — evidence it believes supports the need for a booster.

  • Of 26 new COVID cases in Singapore, 8 local

    The Ministry of Health (MOH) on Monday (12 July) confirmed 26 new COVID-19 cases in Singapore, taking the country's total case count to 62,718.